06 November 2017

Amedeo Smart

Independent Medical Education

Subscriber: th..@boehringer-ingelheim.com

HIV Infection

06 November 2017 | n=41

  1. .
    Frailty in HIV infected people: a new risk factor for bone mineral density loss?: Erratum.
    AIDS 2017;31:2441.

  2. Sah P, Fitzpatrick MC, Pandey A, Galvani AP, et al.
    HIV criminalization exacerbates subpar diagnosis and treatment across the United States: response to the 'Association of HIV diagnosis rates and laws criminalizing HIV exposure in the United States'.
    AIDS 2017;31:2437-2439.

  3. Dalal S, Johnson C, Fonner V, Kennedy CE, et al.
    Reaching people with undiagnosed HIV infection through assisted partner notification.
    AIDS 2017;31:2436-2437.

  4. Joseph Davey DL, Wall KM.
    Need to include couples' HIV counselling and testing as a strategy to improve HIV partner notification services.
    AIDS 2017;31:2435-2436.

  5. Thiebaut R, Hue S, Le Marec F, Lelievre JD, et al.
    Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients.
    AIDS 2017;31:2355-2365.

  6. Saha JM, Liu H, Hu PW, Nikolai BC, et al.
    Proteomic profiling of a primary CD4+ T cell model of HIV-1 latency identifies proteins whose differential expression correlates with reactivation of latent HIV-1.
    AIDS Res Hum Retroviruses 2017.

  7. Nolan D, Rose RR, Rodriguez P, Salemi M, et al.
    The spleen is an HIV-1 sanctuary during cART.
    AIDS Res Hum Retroviruses 2017.

  8. Chaplin B, Imade GE, Onwuamah C, Odaibo G, et al.
    Distinct pattern of TAMs with K65R in patients failing tenofovir-based antiretroviral therapy.
    AIDS Res Hum Retroviruses 2017.

  9. Scott N, Stoove M, Kelly SL, Wilson DP, et al.
    Achieving 90-90-90 HIV targets will not be enough to achieve the HIV incidence reduction target in Australia.
    Clin Infect Dis 2017.

  10. Scheer S, Hsu L, Schwarcz S, Pipkin S, et al.
    Trends in the San Francisco HIV Epidemic in the "Getting to Zero" Era.
    Clin Infect Dis 2017.

  11. Bruce RD, Merlin J, Lum PJ, Ahmed E, et al.
    2017 HIV Medicine Association of Infectious Diseases Society of America Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With Human Immunodeficiency Virus.
    Clin Infect Dis 2017;65:1601-1606.

  12. Yaya I, Costa M, Marcellin F, Miailhes P, et al.
    Gender, alcohol use and fibrosis in HIV-HCV co-infected individuals.
    Clin Infect Dis 2017.

  13. Murnane PM, Strehlau R, Shiau S, Patel F, et al.
    Reply to van de Wijer et. al.
    Clin Infect Dis 2017.

  14. de Ledinghen V, Laforest C, Hezode C, Pol S, et al.
    Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE.
    Clin Infect Dis 2017.

  15. Zhao Y, Wu Z, McGoogan JM, Shi CX, et al.
    Immediate antiretroviral therapy decreases mortality among patients with high CD4 counts in China: a nationwide, retrospective cohort study.
    Clin Infect Dis 2017.

  16. Huaman MA, Ticona E, Miranda G, Kryscio RJ, et al.
    The Relationship between Latent Tuberculosis Infection and Acute Myocardial Infarction.
    Clin Infect Dis 2017.

  17. Balaji AB, An Q, Smith JC, Newcomb ME, et al.
    High HIV incidence and prevalence and associated factors among adolescent sexual minority males, 3 cities, 2015.
    Clin Infect Dis 2017.

  18. Brites C, Abrahao M, Bozza P, Netto EM, et al.
    Infection By Htlv-1 Is Associated With High Levels Of Pro-Inflammatory Cytokines, In Hiv-Hcv Coinfected Patients.
    J Acquir Immune Defic Syndr 2017.

  19. Feller DJ, Zucker J, Yin MT, Gordon P, et al.
    Using Clinical Notes and Natural Language Processing for Automated HIV Risk Assessment.
    J Acquir Immune Defic Syndr 2017.

  20. Mazanderani AH, Moyo F, Kufa T, Sherman GG, et al.
    Declining Baseline Viraemia and Escalating Discordant HIV-1 Confirmatory Results within South Africa's Early Infant Diagnosis Program, 2010-2016.
    J Acquir Immune Defic Syndr 2017.

  21. Mayer KH, Chan PA, Patel R, Flash CA, et al.
    Evolving models and ongoing challenges for HIV pre-exposure prophylaxis implementation in the United States.
    J Acquir Immune Defic Syndr 2017.

  22. French AL, Martin JW, Evans CT, Peters M, et al.
    Macrophage Activation and the Tumor Necrosis Factor Cascade in Hepatitis C Disease Progression Among HIV-Infected Women Participating in the Women's Interagency HIV Study.
    J Acquir Immune Defic Syndr 2017;76:438-444.

  23. Patterson S, Carter A, Nicholson V, Webster K, et al.
    Condomless Sex Among Virally Suppressed Women With HIV With Regular HIV-Serodiscordant Sexual Partners in the Era of Treatment as Prevention.
    J Acquir Immune Defic Syndr 2017;76:372-381.

  24. Sharp A, O'Hagan R, Honermann B, Millett G, et al.
    Setting Targets for HIV: An Evaluation of Indicator Quality and Target Achievement in National Strategic Plans.
    J Acquir Immune Defic Syndr 2017;76:348-355.

  25. Markowitz M, Grossman H, Anderson PL, Grant R, et al.
    Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis.
    J Acquir Immune Defic Syndr 2017;76:e104-e106.

  26. Cabral A, Baeten J, Ngure K, Velloza J, et al.
    Intimate partner violence and self-reported pre-exposure prophylaxis (PrEP) interruptions among HIV-negative partners in HIV serodiscordant couples in Kenya and Uganda.
    J Acquir Immune Defic Syndr 2017.

  27. Veenhuis RT, Freeman ZT, Korleski J, Cohen LK, et al.
    HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells.
    J Clin Invest 2017.

  28. Kirkegaard-Klitbo DM, Langkilde A, Mejer N, Andersen O, et al.
    Soluble Urokinase Plasminogen Activator Receptor Is a Predictor of Incident Non-AIDS Comorbidity and All-Cause Mortality in Human Immunodeficiency Virus Type 1 Infection.
    J Infect Dis 2017;216:819-823.

  29. Newton R, Labo N, Wakeham K, Miley W, et al.
    Kaposi's sarcoma associated herpesvirus in a rural Ugandan cohort: 1992-2008.
    J Infect Dis 2017.

  30. Van Zoest RA, Underwood J, De Francesco D, Sabin CA, et al.
    Structural brain abnormalities in successfully treated HIV infection: associations with disease and cerebrospinal fluid biomarkers.
    J Infect Dis 2017.

  31. Su S, Fairley CK, Sasadeusz J, He J, et al.
    HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    J Med Virol 2017.

  32. Soto-Nava M, Avila-Rios S, Valenzuela-Ponce H, Garcia-Morales C, et al.
    Weaker HLA footprints on HIV in the unique and highly genetically admixed host population of Mexico.
    J Virol 2017.

  33. Malherbe DC, Mendy J, Vang L, Barnette PT, et al.
    Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C SHIV Mucosal Challenge.
    J Virol 2017.

  34. Payne EH, Ramalingam D, Fox DT, Klotman ME, et al.
    Polyploidy And Mitotic Cell Death Are Two Distinct HIV-1 Vpr-Driven Outcomes In Renal Tubule Epithelial Cells.
    J Virol 2017.

  35. Arachchige SP, Henke W, Pramanik A, Kalamvoki M, et al.
    Analysis of Select HSV-1 Proteins for Restriction of Human Immunodeficiency Virus Type 1: The HSV-1 gM Protein Potently Restricts HIV-1 by Preventing the Intracellular Transport and Processing of Env gp160.
    J Virol 2017.

  36. Parolini F, Biswas P, Serena M, Sironi F, et al.
    Stability and expression levels of HLA-C on the cell membrane modulate HIV-1 infectivity.
    J Virol 2017.

  37. Gomez-Moyano E, Crespo-Erchiga V.
    HIV Infection Manifesting as Proximal White Onychomycosis.
    N Engl J Med 2017;377:e26.

  38. Beyrer C, Pozniak A.
    HIV Drug Resistance - An Emerging Threat to Epidemic Control.
    N Engl J Med 2017;377:1605-1607.

  39. Richardson HS, Eyal N, Campbell JI, Haberer JE, et al.
    When Ancillary Care Clashes with Study Aims.
    N Engl J Med 2017;377:1213-1215.

  40. Pinto JA, Capparelli EV, Warshaw M, Zimmer B, et al.
    A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines.
    Pediatr Infect Dis J 2017.

  41. Diaz F, Gregory S, Nakashima H, Viapiano MS, et al.
    Intramuscular delivery of replication-defective herpes simplex virus gives antigen expression in muscle syncytia and improved protection against pathogenic HSV-2 strains.
    Virology 2017;513:129-135.

Display articles in

Amedeo HIV Infection

Data Origin

You selected the following journals for your Amedeo HIV Infection newsletter:

AIDS, AIDS Res Hum Retroviruses, Ann Intern Med, BMJ, Clin Infect Dis, J Acquir Immune Defic Syndr, J Clin Immunol, J Clin Invest, J Infect Dis, J Med Virol, J Virol, JAMA, Lancet, N Engl J Med, Nat Med, Pediatr Infect Dis J, Science, Virology.

To modify the journal selection, please open your Newsletter Management Page. If you don't remember the URL, please submit the email address of your Amedeo subscription.

Your email:

Amedeo HIV Infection

Five-Week Literature

21 January 2019

14 January 2019

07 January 2019

30 December 2018

23 December 2018

06 November 2017

Multidisciplinary Journal Club

  1. Lamy T, Damaj G, Soubeyran P, Gyan E, et al.
    R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL).
    Blood. 2017 Oct 23. pii: blood-2017-07-793984. doi: 10.1182/blood-2017-07-793984

  2. Martinez L, Zhu L, Castellanos ME, Liu Q, et al.
    Glycemic Control and the Prevalence of Tuberculosis Infection: A Population-based Observational Study.
    Clin Infect Dis. 2017 Oct 20. doi: 10.1093.

  3. Bethea E, Chen Q, Hur C, Chung RT, et al.
    Should we treat acute hepatitis C? A decision and cost-effectiveness analysis.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29611.

Every week, Amedeo's Multidisciplinary Journal Club (MJC) presents a selection of outstanding articles. Take a look beyond the horizon.

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016